Human Pathology
Volume 41, Issue 9 , Pages 1205-1209 , September 2010

Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma

  • Adam D. Toll, MD

      Affiliations

    • Department of Pathology, Thomas Jefferson University, Jefferson Pancreas, Biliary and Related Cancer Center, Philadelphia, PA 19107, USA
    • ,
  • Abhijit Dasgupta, PhD

      Affiliations

    • Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Jefferson Pancreas, Biliary and Related Cancer Center, Philadelphia, PA 19107, USA
    • ,
  • Magdalena Potoczek, BS

      Affiliations

    • Department of Pathology, Thomas Jefferson University, Jefferson Pancreas, Biliary and Related Cancer Center, Philadelphia, PA 19107, USA
    • ,
  • Charles J. Yeo, MD

      Affiliations

    • Department of Surgery, Thomas Jefferson University, Jefferson Pancreas, Biliary and Related Cancer Center, Philadelphia, PA 19107, USA
    • ,
  • Celina G. Kleer, MD

      Affiliations

    • Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA
    • ,
  • Jonathan R. Brody, PhD

      Affiliations

    • Department of Pathology, Thomas Jefferson University, Jefferson Pancreas, Biliary and Related Cancer Center, Philadelphia, PA 19107, USA
    • Department of Surgery, Thomas Jefferson University, Jefferson Pancreas, Biliary and Related Cancer Center, Philadelphia, PA 19107, USA
    • ,
  • Agnieszka K. Witkiewicz, MD

      Affiliations

    • Department of Pathology, Thomas Jefferson University, Jefferson Pancreas, Biliary and Related Cancer Center, Philadelphia, PA 19107, USA
    • Corresponding Author InformationCorresponding author. Department of Pathology, Thomas Jefferson University Hospital, Philadelphia, PA, USA

Received 17 November 2009 ,Revised 4 March 2010 ,Accepted 5 March 2010.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Onco. 2007;25:1960–1966
  3. Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 2001;10:687–692
  4. Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Research. 2003;63:3735–3742
  5. Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res. 2008;14:6790–6796
  6. Ezhkova E, Pasolli HA, Parker JS, et al. EZH2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell. 2009;136:1122–1135
  7. Cao Q, Yu J, Dhanasekaran SM, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 2008;27:7274–7284
  8. Saramäki OR, Tammela TLJ, Martikainen PM, et al. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Gene Chromosome Cancer. 2006;45:639–645
  9. Collett K, Eide GE, Arnes J, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res. 2006;12:1168–1174
  10. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. PNAS. 2003;100:11606–11611
  11. Raaphorst FM, Meijer CJ, Fieret E, et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia. 2003;5:481–488
  12. Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003;22:5323–5335
  13. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624–629
  14. McHugh JB, Fullen DR, Ma L, et al. Expression of polycomb group protein EZH2 in nevi and melanoma. J Cutan Pathol. 2007;34:597–600
  15. Hinz S, Weikert S, Magheli A, et al. Expression profile of the polycomb group protein enhancer of zeste homologue 2 and its prognostic relevance in renal cell carcinoma. J Urol. 2009;182:2920–2925
  16. Frixen UH, Behrens J, Sachs M, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol. 1991;113:173–185
  17. Winter JM, Ting AH, Vilardell F, et al. Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res. 2008;14:412–418

☆ The authors have no financial disclosures.

PII: S0046-8177(10)00105-X

doi: 10.1016/j.humpath.2010.03.004

Human Pathology
Volume 41, Issue 9 , Pages 1205-1209 , September 2010

Article Tools

* Image Usage & Resolution